ヘルプ
ヘルプ

検索結果 17,448 件

Lancet

Lancet
紙記録メディアデジタル雑誌
J. Onwhyn<Z53-C416>
国立国会図書館全国の図書館
  •  
  •  
  •  
  •  
  •  
    •  

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
デジタル記事
2023-11The Lancet402 10415p.1835-1847
全国の図書館
  • 掲載誌（ISSN）01406736

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
デジタル記事
2023-09The Lancet402 10408p.1133-1146
全国の図書館
  • 掲載誌（ISSN）01406736

Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial

Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial
デジタル記事
2023-09The Lancet402 10404p.786-797
全国の図書館
  • 掲載誌（ISSN）01406736

Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial

Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial
デジタル記事
2023-06The Lancet401 10394p.2113-2123
全国の図書館
  • 掲載誌（ISSN）01406736

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
デジタル記事
2023-05The Lancet401 10390p.1773-1785
全国の図書館
  • 掲載誌（ISSN）01406736

Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study

Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study
デジタル記事
2023-05The Lancet401 10389p.1669-1680
全国の図書館
  • 掲載誌（ISSN）01406736

Thyroid cancer

Thyroid cancer
デジタル記事
2023-05The Lancet401 10387p.1531-1544
全国の図書館
  • 掲載誌（ISSN）01406736

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
デジタル記事
2023-04The Lancet401 10382p.1079-1090
全国の図書館
  • 掲載誌（ISSN）01406736

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
デジタル記事
2023-04The Lancet401 10383p.1159-1171
全国の図書館
  • 掲載誌（ISSN）01406736

Endovascular treatment versus no endovascular treatment after 6–24 h in patients with ischaemic stroke and collateral flow on CT angiography (MR CLEAN-LATE) in the Netherlands: a multicentre, open-label, blinded-endpoint, randomised, controlled, phase 3 trial

Endovascular treatment versus no endovascular treatment after 6–24 h in patients with ischaemic stroke and collateral flow on CT angiography (MR CLEAN-LATE) in the Netherlands: a multicentre, open-label, blinded-endpoint, randomised, controlled, phase 3 trial
デジタル記事
2023-04The Lancet401 10385p.1371-1380
全国の図書館
  • 掲載誌（ISSN）01406736

Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis

Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis
デジタル記事
2023-03The Lancet401 10379p.833-842
全国の図書館
  • 掲載誌（ISSN）01406736

Unveiling the predatory tactics of the formula milk industry

Unveiling the predatory tactics of the formula milk industry
デジタル記事
2023-02The Lancet401 10375p.409-
全国の図書館
  • 掲載誌（ISSN）01406736

The political economy of infant and young child feeding: confronting corporate power, overcoming structural barriers, and accelerating progress

The political economy of infant and young child feeding: confronting corporate power, overcoming structural barriers, and accelerating progress
デジタル記事
2023-02The Lancet401 10375p.503-524
全国の図書館
  • 掲載誌（ISSN）01406736

Marketing of commercial milk formula: a system to capture parents, communities, science, and policy

Marketing of commercial milk formula: a system to capture parents, communities, science, and policy
デジタル記事
2023-02The Lancet401 10375p.486-502
全国の図書館
  • 掲載誌（ISSN）01406736

How prepared is the world? Identifying weaknesses in existing assessment frameworks for global health security through a One Health approach

How prepared is the world? Identifying weaknesses in existing assessment frameworks for global health security through a One Health approach
デジタル記事
2023-02The Lancet401 10377p.673-687
全国の図書館
  • 掲載誌（ISSN）01406736

Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis

Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis
デジタル記事
2023-02The Lancet401 10377p.664-672
全国の図書館
  • 掲載誌（ISSN）01406736

Breastfeeding: crucially important, but increasingly challenged in a market-driven world

Breastfeeding: crucially important, but increasingly challenged in a market-driven world
デジタル記事
2023-02The Lancet401 10375p.472-485
全国の図書館
  • 掲載誌（ISSN）01406736

Gaining MOMENTUM against anaemic myelofibrosis

Gaining MOMENTUM against anaemic myelofibrosis
デジタル記事
2023-01The Lancet401 10373p.248-249
全国の図書館
  • 掲載誌（ISSN）01406736

An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study

An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
デジタル記事
2023-01The Lancet401 10372p.204-214
全国の図書館
  • 掲載誌（ISSN）01406736